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Recent understanding of HIV-1 pathogenesis mechan-
ism has changed our views about possible mechanisms
of CD4T-cell depletion during infection. Apart from
HIV-1-mediated killing a more comprehensive explana-
tion has appeared that includes T cell exhaustion and
chronic immune activation as a central feature in HIV-1
pathogenesis. While highly active antiretroviral therapy
(HAART) markedly reduces viral load, T cell activation
levels and soluble markers of inflammation remain
abnormally high. Markers of chronic activation, such as
CD38, PD-1 or HLA-DR on T cells, appear to be better
predictors for clinical progression during HIV infection
than HIV RNA levels and CD4Tcell counts alone.
Therefore, a better understanding of HIV-índuced
immune activation and the design of new immunomo-
dulatory approches in combination with HAART are
needed.
We have generated an efficient model of human stem
cells (HSCs) engraftment in NOD/LtsZ-scidlL-2R
null
(NSG) mice that supports chronic HIV infection with
high plasma viral loads. HIV-1 infection in these huma-
nized mice is characterized by widespread immune acti-
vation with increased expression of PD-1, HLA-DR,
CD38, CD69, CD25 and other immune activation mar-
kers. These humanized mice provide an effective in vivo
system for the assessing novel approaches for their
potential in suppressing chronic immune activation dur-
ing HIV-1 infection, in absence of interference of antire-
troviral therapy. In this study, we evaluated in vivo the
benefits of two novel approaches aimed at reducing
HIV-induced immune activation.
Minocycline is an antibiotic of the tetracycline family
with anti-inflammatory and immunomodulatory proper-
ties affecting CD4 T cells activation by a mechanism
involving the inhibition of the NF-AT1 transcription
factor activity. We hypothesized that this antibiotic
could suppress the HIV-1-induced chronic immune acti-
vation and thus, limit the HIV pathogenesis when com-
bined to HAART. Therefore, we treated HIV-1 (JRCSF)
infected-humanized NSG mice with minocycline
(100mg/kg/day) for 60 days. We next evaluated the
expression, by flow cytometry, of several T cells activa-
tion markers together with CD4
+T cells counts. Our
data suggest that minocycline is effective in suppressing
HIV-1 induced immune activation in peripheral blood
and lymphoid organs (spleen, lymph nodes and bone
marrow). Levels of cellular immune activation markers
such as PD-1, HLA-DR, CD38, CD69, CD25, CD28 and
CTLA-4 were significantly lower in minocycline treated
group. These immunological benefits of minocycline
were correlated with higher CD4
+Tc e l lc o u n t si nt h e
treated group.
The immune activation which is associated with retro-
viral infection is also associated with increased levels of
intracytoplasmic cyclic AMP which could act as a posi-
tive feedback loop in the infection since several reports
have suggested that cAMP and downstream signaling
pathways play an important role in the permissivity of
susceptible cells to HIV infection and replication. We
have used a peptide which prevents the binding of the
catalytic subunit of PKA type I to its anchoring protein
and therefore blocks most effects of cyclic AMP within
lymphocytes and monocytes (RIAD peptide). Mice were
treated with 3.5 mg/kg of RIAD peptide weekly. Treat-
ment of humanized mice with RIAD peptide limited
viral replication after high dose of HIV intraperitoneal
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cyclic AMP.
Further experiments are needed to better appreciate
the therapeutic potential of these novel therapies in the
suppression of HIV-induced chronic immune activation.
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